

COUNTER et al  
Appl. No. 10/554,295  
March 1, 2010

RECEIVED  
CENTRAL FAX CENTER

MAR 01 2010

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1.-7. (Cancelled).
8. (Previously Presented) An isolated nucleic acid sequence encoding a chimeric molecule comprising a polypeptide having telomerase catalytic activity fused to a telomere binding polypeptide, wherein said polypeptide having telomerase catalytic activity comprises a catalytic subunit of a mammalian telomerase reverse transcriptase.
9. (Currently Amended) [[The]] A nucleic acid sequence according to claim 8 encoding a chimeric molecule comprising a polypeptide having telomerase catalytic activity fused to a telomere binding polypeptide, wherein said polypeptide having telomerase catalytic activity comprises a catalytic subunit of a mammalian telomerase reverse transcriptase, wherein said nucleic acid sequence encodes a molecule comprising the protein encoded by the nucleotide sequence set forth in SEQ ID NO:1.
10. (Previously Presented) An isolated nucleic acid sequence encoding a chimeric molecule comprising a polypeptide having telomerase catalytic activity fused to a telomere binding polypeptide wherein said nucleic acid sequence comprises the nucleotide sequence set forth in SEQ ID NO:1.
11. (Original) An expression construct comprising said nucleic acid sequence according to claim 8 operably linked to a promoter.
12. (Original) A vector comprising the nucleic acid sequence according to claim 8.

COUNTER et al  
Appl. No. 10/554,295  
March 1, 2010

13. (Original) The vector according to claim 12 wherein said vector is a viral vector.
14. (Original) The vector according to claim 13 wherein said viral vector is a retroviral vector, adeno-associated viral vector, lentiviral vector or adenoviral vector.
15. (Original) A liposome comprising the nucleic acid sequence according to claim 8.
16. (Original) A composition comprising the nucleic acid sequence according to claim 8 encapsulated in a polymer.
17. (Original) An isolated cell comprising the nucleic acid sequence according to claim 8.
18. (Original) The cell according to claim 17 wherein said cell is a stem or progenitor cell.
19. (Original) The cell according to claim 17 wherein said cell is an epithelial cell or a fibroblast.
20. (Original) The cell according to claim 17 wherein said cell is a muscle cell, nervous system cell, or keratinocyte.
21. (Original) The cell according to claim 17 wherein said cell is a human cell.
22. (Original) The cell according to claim 17 wherein said cell is immortal.

COUNTER et al  
Appl. No. 10/554,295  
March 1, 2010

23. (Original) A method of producing a protein comprising culturing said cell according to claim 17 under conditions such that said nucleic acid sequence is expressed and said molecule is thereby produced.

24. (Cancelled).

25. (Previously Presented) The nucleic acid according to claim 8 wherein said telomere binding polypeptide is selected from the group consisting of Pot1, TRF1, TRF2, PinX1, Rap1, Tin2, Tankyrase, TANK2 and Ku70/80.

26. (Previously Presented) The nucleic acid according to claim 25 wherein said telomere binding polypeptide is hPot1.

27. (Previously Presented) The nucleic acid according to claim 25 wherein said telomere binding polypeptide is present in said molecule N-terminal to said polypeptide having telomerase catalytic activity.

28. (Previously Presented) The nucleic acid according to claim 25 wherein said telomere binding polypeptide is directly linked to said polypeptide having telomerase catalytic activity.

29. (Previously Presented) An expression construct comprising said nucleic acid sequence according to claim 25 operably linked to a promoter.

30. (Previously Presented) A vector comprising the nucleic acid sequence according to claim 25.

COUNTER et al  
Appl. No. 10/554,295  
March 1, 2010

31. (Previously Presented) The vector according to claim 30 wherein said vector is a viral vector.
32. (Previously Presented) The vector according to claim 31 wherein said viral vector is a retroviral vector, adeno-associated viral vector, lentiviral vector or adenoviral vector.
33. (Previously Presented) A liposome comprising the nucleic acid sequence according to claim 25.
34. (Previously Presented) A composition comprising the nucleic acid sequence according to claim 25 encapsulated in a polymer.
35. (Previously Presented) An isolated cell comprising the nucleic acid sequence according to claim 25.
36. (Previously Presented) The cell according to claim 35 wherein said cell is a stem or progenitor cell.
37. (Previously Presented) The cell according to claim 35 wherein said cell is an epithelial cell or a fibroblast.
38. (Previously Presented) The cell according to claim 35 wherein said cell is a muscle cell, nervous system cell, or keratinocyte.
39. (Previously Presented) The cell according to claim 35 wherein said cell is a human cell.

COUNTER et al  
Appl. No. 10/554,295  
March 1, 2010

40. (Previously Presented) The cell according to claim 35 wherein said cell is immortal.
41. (Previously Presented) A method of producing a protein comprising culturing said cell according to claim 35 under conditions such that said nucleic acid sequence is expressed and said molecule is thereby produced.
42. (New) The nucleic acid according to claim 8 wherein said polypeptide having telomerase catalytic activity comprises a catalytic subunit of human telomerase reverse transcriptase.
43. (New) The nucleic acid according to claim 25 wherein said polypeptide having telomerase catalytic activity comprises a catalytic subunit of human telomerase reverse transcriptase.
44. (New) The isolated nucleic acid according to claim 25 wherein said telomerase binding polypeptide is selected from the group consisting of Pot1, TRF1, and TRF2.
45. (New) The nucleic acid according to claim 42 wherein said telomerase binding polypeptide is selected from the group consisting of Pot1, TRF1, and TRF2.